Allergan PLC (AGN)

Statement of Cash Flows
Quarterly Data

Difficulty: Beginner

The cash flow statement provides information about a company’s cash receipts and cash payments during an accounting period, showing how these cash flaws link the ending cash balance to the beginning balance shown on the company’s statement of financial position.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Allergan PLC, Consolidated Statement of Cash Flows (quarterly data)

USD $ in thousands

	3 months ended	Dec 31, 2018		Sep 30, 2018		Jun 30, 2018		Mar 31, 2018		Dec 31, 2017		Sep 30, 2017		Jun 30, 2017		Mar 31, 2017		Dec 31, 2016		Sep 30, 2016		Jun 30, 2016		Mar 31, 2016		Dec 31, 2015		Sep 30, 2015		Jun 30, 2015		Mar 31, 2015		Dec 31, 2014		Sep 30, 2014		Jun 30, 2014		Mar 31, 2014
	Net income (loss)
	Depreciation
	Amortization
	Provision for inventory reserve
	Share-based compensation
	Deferred income tax benefit
	Pre-tax gain sale of generics business
	Non-cash tax effect of gain on sale of generics business
	Goodwill impairment
	In-process research and development impairments
	(Gain) loss on asset sales and impairments, net
	Net income impact of other-than-temporary loss on investment in Teva securities
	Gain on sale of Teva securities, net
	Loss on Teva securities
	Charge to settle Teva related matters
	Loss on forward sale of Teva shares
	Amortization of inventory step-up
	Gain on sale of business
	Non-cash extinguishment of debt
	Cash discount related to extinguishment of debt
	Amortization of deferred financing costs
	Contingent consideration adjustments, including accretion
	Excess tax benefit from stock-based compensation
	Impact of assets held for sale
	Other, net
	(Increase) decrease in accounts receivable, net
	(Increase) decrease in inventories
	(Increase) decrease in prepaid expenses and other current assets
	Increase (decrease) in accounts payable and accrued expenses
	Increase (decrease) in income and other taxes payable
	Increase (decrease) in other assets and liabilities
	Changes in assets and liabilities, net of effects of acquisitions
	Reconciliation to net cash provided by operating activities
	Net cash provided by operating activities
	Additions to property, plant and equipment
	Additions to product rights and other intangibles
	Sale of generics business
	Additions to investments
	Proceeds from sale of investments and other assets
	Payments to settle Teva related matters
	Proceeds from sales of property, plant and equipment
	Acquisitions of businesses, net of cash acquired
	Net cash (used in) provided by investing activities
	Proceeds from borrowings of long-term indebtedness, including credit facility
	Proceeds from forward sale of Teva securities
	Debt issuance and other financing costs
	Payments on debt, including capital lease obligations and credit facility
	Cash charge related to extinguishment of debt
	Proceeds from issuance of preferred shares
	Proceeds from issuance of ordinary shares
	Proceeds from stock plans
	Payments of contingent consideration and other financing
	Payments to settle Teva related matters
	Repurchase of ordinary shares
	Dividends paid
	Excess tax benefit from stock-based compensation
	Net cash provided by (used in) financing activities
	Effect of currency exchange rate changes on cash and cash equivalents
	Movement in cash held for sale
	Net increase (decrease) in cash and cash equivalents

Item	Description	The company
Net cash provided by operating activities	Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.	Allergan PLC’s net cash provided by operating activities increased from Q2 2018 to Q3 2018 and from Q3 2018 to Q4 2018.
Net cash (used in) provided by investing activities	Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.	Allergan PLC’s net cash (used in) provided by investing activities declined from Q2 2018 to Q3 2018 and from Q3 2018 to Q4 2018.
Net cash provided by (used in) financing activities	Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.	Allergan PLC’s net cash provided by (used in) financing activities declined from Q2 2018 to Q3 2018 but then increased from Q3 2018 to Q4 2018 exceeding Q2 2018 level.

	Allergan PLC	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

Allergan PLC (AGN)

Statement of Cash FlowsQuarterly Data

Statement of Cash Flows
Quarterly Data